ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Song S, Xie M, Scott A, Jin J, Ma L, Dong X
. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther. 2017; 17(2):443-454.
PMC: 5805581.
DOI: 10.1158/1535-7163.MCT-17-0560.
View
2.
Heethuis S, Goense L, van Rossum P, Borggreve A, Mook S, Voncken F
. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer. Acta Oncol. 2018; 57(9):1201-1208.
DOI: 10.1080/0284186X.2018.1473637.
View
3.
Lagergren P, Avery K, Hughes R, Barham C, Alderson D, Falk S
. Health-related quality of life among patients cured by surgery for esophageal cancer. Cancer. 2007; 110(3):686-93.
DOI: 10.1002/cncr.22833.
View
4.
Goense L, van Rossum P, Xi M, Maru D, Carter B, Meijer G
. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol. 2018; 25(6):1598-1607.
PMC: 5928173.
DOI: 10.1245/s10434-018-6435-4.
View
5.
van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B
. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84.
DOI: 10.1056/NEJMoa1112088.
View